Original data (with adjusted standard errors for multi-arm studies):

              treat1      treat2      TE   seTE seTE.adj.f seTE.adj.r narms multiarm
10           placebo    zolpidem  0.0379 0.1077     0.1077     0.2079     2         
12       eszopiclone     placebo -0.5283 0.4674     0.4674     0.5001     2         
45           placebo  suvorexant  0.4633 0.0965     0.0965     0.2023     2         
46           placebo  suvorexant  0.4385 0.1070     0.1070     0.2075     2         
47           placebo    zolpidem  0.8141 0.4546     0.4546     0.4882     2         
51          BZD-long     placebo -0.0473 0.2458     0.2840     0.3578     3        *
51         BZD-short     placebo  0.2821 0.2836     0.3991     0.4455     3        *
51          BZD-long   BZD-short -0.3294 0.2469     0.2859     0.3595     3        *
52          BZD-long   zopiclone  0.0792 0.6327     0.6327     0.6572     2         
54  BZD-intermediate    BZD-long  0.0715 0.5775     0.5775     0.6043     2         
55          BZD-long   BZD-short  0.3004 0.5806     0.5806     0.6072     2         
56  BZD-intermediate   BZD-short  0.6719 0.5934     0.5934     0.6195     2         
60           doxepin     placebo -0.4267 0.1584     0.1584     0.2382     2         
61           doxepin     placebo -0.4135 0.1417     0.1417     0.2274     2         
70         melatonin     placebo  0.2601 0.3176     0.3176     0.3640     2         
71          BZD-long   BZD-short  0.2683 0.5799     0.5799     0.6066     2         
77       eszopiclone     placebo -0.2518 0.1259     0.1259     0.2179     2         
80           placebo    zolpidem  1.3541 0.6401     0.6401     0.6643     2         
81           placebo    zolpidem  1.0571 0.6164     0.6164     0.6415     2         
83  BZD-intermediate     placebo -0.6926 0.3586     0.3586     0.4003     2         
99      daridorexant    zolpidem -0.2831 0.1584     0.1831     0.2845     3        *
99           placebo    zolpidem  0.0122 0.1826     0.2574     0.3293     3        *
99      daridorexant     placebo -0.2953 0.1585     0.1832     0.2846     3        *
112          placebo    zolpidem  0.4571 0.2125     0.2125     0.2771     2         
114          placebo    zolpidem  0.7140 0.1463     0.1463     0.2303     2         
122          placebo   zopiclone  0.5786 0.4015     0.4015     0.4391     2         
134          placebo    zaleplon  0.1309 0.2044     0.2044     0.2709     2         
137          placebo    zolpidem  0.3864 0.1432     0.1432     0.2283     2         
140        BZD-short    zolpidem -0.5457 0.2535     0.3160     0.3838     3        *
140          placebo    zolpidem  0.0546 0.2408     0.2864     0.3594     3        *
140        BZD-short     placebo -0.6002 0.2524     0.3132     0.3815     3        *
144      eszopiclone     placebo -0.3163 0.1259     0.1259     0.2179     2         
145          placebo   ramelteon -0.0980 0.1218     0.1218     0.2156     2         
153      lemborexant    zolpidem -0.2360 0.0771     0.0866     0.2332     3        *
153          placebo    zolpidem  0.3840 0.0953     0.1386     0.2528     3        *
153      lemborexant     placebo -0.6199 0.0844     0.0985     0.2400     3        *
154      lemborexant     placebo  0.0319 0.1842     0.1842     0.2561     2         
158          placebo seltorexant  0.1910 0.1397     0.1562     0.2682     3        *
158          placebo    zolpidem  0.0456 0.1709     0.2713     0.3251     3        *
158      seltorexant    zolpidem -0.1453 0.1389     0.1550     0.2671     3        *
159     daridorexant     placebo -0.5239 0.0706     0.0706     0.1913     2         
160     daridorexant     placebo -0.3153 0.0810     0.0810     0.1954     2         

Number of treatment arms (by study):
    narms
10      2
12      2
45      2
46      2
47      2
51      3
52      2
54      2
55      2
56      2
60      2
61      2
70      2
71      2
77      2
80      2
81      2
83      2
99      3
112     2
114     2
122     2
134     2
137     2
140     3
144     2
145     2
153     3
154     2
158     3
159     2
160     2

Results (fixed effects model):

              treat1      treat2     SMD             95%-CI    Q leverage
10           placebo    zolpidem  0.2700 [ 0.1753;  0.3647] 4.64     0.20
12       eszopiclone     placebo -0.2926 [-0.4640; -0.1212] 0.25     0.04
45           placebo  suvorexant  0.4521 [ 0.3117;  0.5926] 0.01     0.55
46           placebo  suvorexant  0.4521 [ 0.3117;  0.5926] 0.02     0.45
47           placebo    zolpidem  0.2700 [ 0.1753;  0.3647] 1.43     0.01
51          BZD-long     placebo -0.3633 [-0.7396;  0.0131] 1.24        .
51         BZD-short     placebo -0.4176 [-0.7421; -0.0932] 3.07        .
51          BZD-long   BZD-short  0.0544 [-0.3100;  0.4188] 1.80        .
52          BZD-long   zopiclone  0.1762 [-0.5403;  0.8928] 0.02     0.33
54  BZD-intermediate    BZD-long -0.0435 [-0.6388;  0.5517] 0.04     0.28
55          BZD-long   BZD-short  0.0544 [-0.3100;  0.4188] 0.18     0.10
56  BZD-intermediate   BZD-short  0.0108 [-0.5680;  0.5897] 1.24     0.25
60           doxepin     placebo -0.4194 [-0.6263; -0.2124] 0.00     0.44
61           doxepin     placebo -0.4194 [-0.6263; -0.2124] 0.00     0.56
70         melatonin     placebo  0.2601 [-0.3623;  0.8825] 0.00     1.00
71          BZD-long   BZD-short  0.0544 [-0.3100;  0.4188] 0.14     0.10
77       eszopiclone     placebo -0.2926 [-0.4640; -0.1212] 0.11     0.48
80           placebo    zolpidem  0.2700 [ 0.1753;  0.3647] 2.87     0.01
81           placebo    zolpidem  0.2700 [ 0.1753;  0.3647] 1.63     0.01
83  BZD-intermediate     placebo -0.4068 [-0.9535;  0.1399] 0.64     0.60
99      daridorexant    zolpidem -0.1625 [-0.2929; -0.0320] 0.43        .
99           placebo    zolpidem  0.2700 [ 0.1753;  0.3647] 1.00        .
99      daridorexant     placebo -0.4325 [-0.5292; -0.3357] 0.56        .
112          placebo    zolpidem  0.2700 [ 0.1753;  0.3647] 0.78     0.05
114          placebo    zolpidem  0.2700 [ 0.1753;  0.3647] 9.21     0.11
122          placebo   zopiclone  0.5395 [-0.1337;  1.2127] 0.01     0.73
134          placebo    zaleplon  0.1309 [-0.2697;  0.5315] 0.00     1.00
137          placebo    zolpidem  0.2700 [ 0.1753;  0.3647] 0.66     0.11
140        BZD-short    zolpidem -0.1476 [-0.4783;  0.1830] 1.59        .
140          placebo    zolpidem  0.2700 [ 0.1753;  0.3647] 0.57        .
140        BZD-short     placebo -0.4176 [-0.7421; -0.0932] 0.34        .
144      eszopiclone     placebo -0.2926 [-0.4640; -0.1212] 0.04     0.48
145          placebo   ramelteon -0.0980 [-0.3368;  0.1408] 0.00     1.00
153      lemborexant    zolpidem -0.2205 [-0.3496; -0.0914] 0.03        .
153          placebo    zolpidem  0.2700 [ 0.1753;  0.3647] 0.68        .
153      lemborexant     placebo -0.4905 [-0.6197; -0.3613] 1.73        .
154      lemborexant     placebo -0.4905 [-0.6197; -0.3613] 8.04     0.13
158          placebo seltorexant  0.3041 [ 0.0832;  0.5249] 0.52        .
158          placebo    zolpidem  0.2700 [ 0.1753;  0.3647] 0.68        .
158      seltorexant    zolpidem -0.0341 [-0.2547;  0.1866] 0.52        .
159     daridorexant     placebo -0.4325 [-0.5292; -0.3357] 1.68     0.49
160     daridorexant     placebo -0.4325 [-0.5292; -0.3357] 2.09     0.37

Results (random effects model):

              treat1      treat2     SMD             95%-CI
10           placebo    zolpidem  0.2818 [ 0.1265;  0.4370]
12       eszopiclone     placebo -0.3052 [-0.5938; -0.0166]
45           placebo  suvorexant  0.4512 [ 0.1672;  0.7351]
46           placebo  suvorexant  0.4512 [ 0.1672;  0.7351]
47           placebo    zolpidem  0.2818 [ 0.1265;  0.4370]
51          BZD-long     placebo -0.3586 [-0.8080;  0.0908]
51         BZD-short     placebo -0.4292 [-0.8143; -0.0441]
51          BZD-long   BZD-short  0.0706 [-0.3590;  0.5002]
52          BZD-long   zopiclone  0.1765 [-0.6036;  0.9567]
54  BZD-intermediate    BZD-long -0.0278 [-0.6823;  0.6267]
55          BZD-long   BZD-short  0.0706 [-0.3590;  0.5002]
56  BZD-intermediate   BZD-short  0.0428 [-0.5909;  0.6765]
60           doxepin     placebo -0.4198 [-0.7421; -0.0975]
61           doxepin     placebo -0.4198 [-0.7421; -0.0975]
70         melatonin     placebo  0.2601 [-0.4532;  0.9735]
71          BZD-long   BZD-short  0.0706 [-0.3590;  0.5002]
77       eszopiclone     placebo -0.3052 [-0.5938; -0.0166]
80           placebo    zolpidem  0.2818 [ 0.1265;  0.4370]
81           placebo    zolpidem  0.2818 [ 0.1265;  0.4370]
83  BZD-intermediate     placebo -0.3864 [-0.9857;  0.2129]
99      daridorexant    zolpidem -0.1427 [-0.4000;  0.1146]
99           placebo    zolpidem  0.2818 [ 0.1265;  0.4370]
99      daridorexant     placebo -0.4244 [-0.6474; -0.2014]
112          placebo    zolpidem  0.2818 [ 0.1265;  0.4370]
114          placebo    zolpidem  0.2818 [ 0.1265;  0.4370]
122          placebo   zopiclone  0.5351 [-0.1938;  1.2641]
134          placebo    zaleplon  0.1309 [-0.4001;  0.6619]
137          placebo    zolpidem  0.2818 [ 0.1265;  0.4370]
140        BZD-short    zolpidem -0.1474 [-0.5473;  0.2525]
140          placebo    zolpidem  0.2818 [ 0.1265;  0.4370]
140        BZD-short     placebo -0.4292 [-0.8143; -0.0441]
144      eszopiclone     placebo -0.3052 [-0.5938; -0.0166]
145          placebo   ramelteon -0.0980 [-0.5205;  0.3245]
153      lemborexant    zolpidem -0.1064 [-0.3982;  0.1855]
153          placebo    zolpidem  0.2818 [ 0.1265;  0.4370]
153      lemborexant     placebo -0.3881 [-0.6682; -0.1080]
154      lemborexant     placebo -0.3881 [-0.6682; -0.1080]
158          placebo seltorexant  0.3095 [-0.0695;  0.6885]
158          placebo    zolpidem  0.2818 [ 0.1265;  0.4370]
158      seltorexant    zolpidem -0.0277 [-0.4066;  0.3512]
159     daridorexant     placebo -0.4244 [-0.6474; -0.2014]
160     daridorexant     placebo -0.4244 [-0.6474; -0.2014]

Number of studies: k = 32
Number of pairwise comparisons: m = 42
Number of observations: o = 6644
Number of treatments: n = 15
Number of designs: d = 20

Fixed effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                     SMD             95%-CI     z  p-value
BZD-intermediate -0.4068 [-0.9535;  0.1399] -1.46   0.1447
BZD-long         -0.3633 [-0.7396;  0.0131] -1.89   0.0585
BZD-short        -0.4176 [-0.7421; -0.0932] -2.52   0.0116
daridorexant     -0.4325 [-0.5292; -0.3357] -8.76 < 0.0001
doxepin          -0.4194 [-0.6263; -0.2124] -3.97 < 0.0001
eszopiclone      -0.2926 [-0.4640; -0.1212] -3.35   0.0008
lemborexant      -0.4905 [-0.6197; -0.3613] -7.44 < 0.0001
melatonin         0.2601 [-0.3623;  0.8825]  0.82   0.4127
placebo                .                  .     .        .
ramelteon         0.0980 [-0.1408;  0.3368]  0.80   0.4211
seltorexant      -0.3041 [-0.5249; -0.0832] -2.70   0.0070
suvorexant       -0.4521 [-0.5926; -0.3117] -6.31 < 0.0001
zaleplon         -0.1309 [-0.5315;  0.2697] -0.64   0.5219
zolpidem         -0.2700 [-0.3647; -0.1753] -5.59 < 0.0001
zopiclone        -0.5395 [-1.2127;  0.1337] -1.57   0.1162

Random effects model

Treatment estimate (sm = 'SMD', comparison: other treatments vs 'placebo'):
                     SMD             95%-CI     z p-value            95%-PI
BZD-intermediate -0.3864 [-0.9857;  0.2129] -1.26  0.2064 [-1.1199; 0.3472]
BZD-long         -0.3586 [-0.8080;  0.0908] -1.56  0.1179 [-0.9604; 0.2432]
BZD-short        -0.4292 [-0.8143; -0.0441] -2.18  0.0290 [-0.9788; 0.1204]
daridorexant     -0.4244 [-0.6474; -0.2014] -3.73  0.0002 [-0.8622; 0.0134]
doxepin          -0.4198 [-0.7421; -0.0975] -2.55  0.0107 [-0.9221; 0.0825]
eszopiclone      -0.3052 [-0.5938; -0.0166] -2.07  0.0382 [-0.7840; 0.1736]
lemborexant      -0.3881 [-0.6682; -0.1080] -2.72  0.0066 [-0.8613; 0.0850]
melatonin         0.2601 [-0.4532;  0.9735]  0.71  0.4748 [-0.5800; 1.1002]
placebo                .                  .     .       .                 .
ramelteon         0.0980 [-0.3245;  0.5205]  0.45  0.6493 [-0.4815; 0.6776]
seltorexant      -0.3095 [-0.6885;  0.0695] -1.60  0.1095 [-0.8543; 0.2354]
suvorexant       -0.4512 [-0.7351; -0.1672] -3.11  0.0018 [-0.9269; 0.0245]
zaleplon         -0.1309 [-0.6619;  0.4001] -0.48  0.6290 [-0.8030; 0.5412]
zolpidem         -0.2818 [-0.4370; -0.1265] -3.56  0.0004 [-0.6855; 0.1220]
zopiclone        -0.5351 [-1.2641;  0.1938] -1.44  0.1502 [-1.3901; 0.3198]

Quantifying heterogeneity / inconsistency:
tau^2 = 0.0316; tau = 0.1778; I^2 = 54.4% [27.7%; 71.3%]

Tests of heterogeneity (within designs) and inconsistency (between designs):
                    Q d.f. p-value
Total           50.48   23  0.0008
Within designs  23.91   12  0.0209
Between designs 26.57   11  0.0053
[1] "A total of 15 treatments are included in the network."
[1] "A total of 32 studies are included in this analysis."
[1] "A total of 6644 participants are included in this analysis."
[1] "The following studies were included in this analysis: 10 12 45 46 47 51 52 54 55 56 60 61 70 71 77 80 81 83 99 112 114 122 134 137 140 144 145 153 154 158 159 160"
[1] "Estimated heterogeneity tau-squared0.03"
[1] "Global test for inconsistency, p-value 0.00534 (Q=27, d.o.f. 11)"
[1] "File created on 2022-06-01"
